 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Merck & Co., Inc. (MRK) operates as a healthcare company worldwide. 
It operates through two segments, Pharmaceutical and Animal Health.
The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.
Shares of this Dow component have formed a bullish "cup and handle" and are expected to move higherfrom this formation. On April 28th, it reported 1st Quarter March 2022 earnings of $2.14 per share on revenue of $15.9 billion. The consensus earnings estimate was $1.81 per share on revenue of $14.6 billion. Revenue grew 31.6% on a year-over-year basis.
The company said it expects 2022 earnings of $7.24 to $7.36 per share on revenue of $56.90 billion to $58.10 billion. The company's previous guidance was earnings of $7.12 to $7.27 per share on revenue of $56.10 billion to $57.60 billion for the year ending December 31, 2022.
Entry Point: $89.00
Stop Loss: $85.00
Trading Range: $70.89 - $91.40
Target Price: $98.00
MRK closed at $91.55
